No Data
Express News | Eli Lilly and Co reached a strategic partnership with Radionetics.
Fighting Words: Lilly and Novo Swat Back at the Biden/Sanders Call for Lower GLP-1 Prices
Eli Lilly and Co finally obtained approval from the USA FDA, and there will be a two-strong competition in the field of Alzheimer's disease.
① The FDA announced on its official website that the drug “donanemab-azbt” developed by Eli Lilly has been approved to treat early-stage Alzheimer's patients with mild cognitive impairment; ② Eli Lilly executives wrote that Kisunla has shown very meaningful results, and patients urgently need this effective treatment plan.
The Investment Guide for the 2024 USA Election is here! The best deployment time has come. Which US stocks are worth paying attention to?
Bank of America stated that the average monthly ROI of the S&P 500 index in the fourth year of a presidential cycle shows mediocre performance from January to May, a summer rebound from June to August, a fall before the election in September to October, and a post-election rebound in November and December.
Sector Update: Health Care
Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.4%. The iShares Biotechnology ETF (IBB)
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,023
Morgan Stanley analyst Terence Flynn maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,023.According to TipRanks data, the analyst has a success rate of 65.0